Prime Medicine Inc (NASDAQ:PRME) has a beta value of 1.92 and has seen 1.53 million shares traded in the last trading session. The company, currently valued at $452.21M, closed the last trade at $3.20 per share which meant it gained $0.23 on the day or 7.74% during that session. The PRME stock price is -208.12% off its 52-week high price of $9.86 and 10.94% above the 52-week low of $2.85. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.47 million shares traded. The 3-month trading volume is 1.52 million shares.
The consensus among analysts is that Prime Medicine Inc (PRME) is Buy stock at the moment, with a recommendation rating of 1.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.39.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Prime Medicine Inc (NASDAQ:PRME) trade information
Sporting 7.74% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the PRME stock price touched $3.20 or saw a rise of 5.33%. Year-to-date, Prime Medicine Inc shares have moved -63.88%, while the 5-day performance has seen it change -4.33%. Over the past 30 days, the shares of Prime Medicine Inc (NASDAQ:PRME) have changed -23.81%. Short interest in the company has seen 15.79 million shares shorted with days to cover at 5.78.
Wall Street analysts have a consensus price target for the stock at $17, which means that the shares’ value could jump 81.18% from current levels. The projected low price target is $12.0 while the price target rests at a high of $23.0. In that case, then, we find that the current price level is -618.75% off the targeted high while a plunge would see the stock gain -275.0% from current levels.
Prime Medicine Inc (PRME) estimates and forecasts
Figures show that Prime Medicine Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -53.79% over the past 6 months, with this year growth rate of 16.26%, compared to 18.00% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
8 analysts offering their estimates for the company have set an average revenue estimate of 287.5k for the current quarter. 6 have an estimated revenue figure of 3.75M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -193.88% over the past 5 years.
PRME Dividends
Prime Medicine Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Prime Medicine Inc (NASDAQ:PRME)’s Major holders
Insiders own 23.91% of the company shares, while shares held by institutions stand at 62.31% with a share float percentage of 81.88%. Investors are also buoyed by the number of investors in a company, with Prime Medicine Inc having a total of 166.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Genomic Revolution ETF and ARK ETF Tr-ARK Innovation ETF . As of Oct 31, 2024 , the former fund manager holds about 2.09% shares in the company for having 2.74 shares of worth $8.76 million while later fund manager owns 2.41 shares of worth $7.7 million as of Oct 31, 2024 , which makes it owner of about 1.83% of company’s outstanding stock.
